{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T06:07:42Z","timestamp":1779084462752,"version":"3.51.4"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Darolutamide is the next-generation androgen receptor inhibitor approved for the treatment of advanced prostate cancer, including non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC). However, the efficacy and safety of darolutamide are nonetheless worthy of further clinical studies. The objective of this meta-analysis was to evaluate the overall survival, metastasis-free survival and various specific adverse events of darolutamide combination therapy in patients with mHSPC or nmCRPC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This meta-analysis was performed on PubMed, EMBASE, Web of Science,\n                      <jats:ext-link>ClinicalTrials.gov<\/jats:ext-link>\n                      , and the Cochrane Library for English-language articles to collect randomized clinical trials of darolutamide combination therapy in mHSPC and nmCRPC from the start of the database to 15 January 2026. The primary efficacy outcomes were overall survival and metastasis-free survival. Key safety outcomes included the total number of overall adverse events, the total number of grade \u22653 adverse events and serious adverse events, and the occurrence of specific adverse events of interest. The risk of bias was assessed by the Cochrane risk-of-bias tool for randomized trials (RoB 2). Publication bias was assessed by funnel plots.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>There were 8 research articles from 3 randomized clinical trials with 3,483 patients involved in this meta-analysis, including 1,509 nmCRPC patients from the ARAMIS trial, 1974 mHSPC patients from the ARASENS and ARANOTE trials. Combining darolutamide with ADT significantly prolonged overall survival (OS) and metastasis-free survival (MFS) in nmCRPC patients compared with placebo plus ADT. And darolutamide plus ADT with or without docetaxel also showed favorable overall survival in mHSPC patients. Subgroup meta-analyses of OS among mHSPC patients for baseline total PSA (tPSA) values and Gleason scores showed the beneficial efficacy of darolutamide in mHSPC. The addition of darolutamide in ADT and\/or docetaxel did not lead to serious adverse events, like heart failure, bone fracture and hypertension, in both nmCRPC and mHSPC patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Darolutamide combination therapy was beneficial to the prognosis and demonstrated a favorable safety profile in patients with advanced prostate cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>Identifier CRD420251145736.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1818807","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T05:42:11Z","timestamp":1779082931000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["The efficacy and safety of darolutamide combination therapy in advanced prostate cancer: a systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.3389","volume":"17","author":[{"given":"Xi","family":"Cao","sequence":"first","affiliation":[{"name":"Department of Urology, Kidney and Urology Center, Scientific Research Center, Pelvic Floor Disorders Center, The Seventh Affiliated Hospital, Sun Yat-sen University","place":["Shenzhen, Guangdong, China"]},{"name":"School of Medicine, Sun Yat-sen University","place":["Shenzhen, Guangdong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Di","family":"Li","sequence":"additional","affiliation":[{"name":"School of Medicine, Sun Yat-sen University","place":["Shenzhen, Guangdong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuoyi","family":"Han","sequence":"additional","affiliation":[{"name":"School of Medicine, Sun Yat-sen University","place":["Shenzhen, Guangdong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenghao","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Andrology, The Seventh Affiliated Hospital, Sun Yat-sen University","place":["Shenzhen, Guangdong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junhao","family":"Chu","sequence":"additional","affiliation":[{"name":"Department of Andrology, The Seventh Affiliated Hospital, Sun Yat-sen University","place":["Shenzhen, Guangdong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changze","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Andrology, The Seventh Affiliated Hospital, Sun Yat-sen University","place":["Shenzhen, Guangdong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongyin","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Burns and Plastic Surgery, The Seventh Affiliated Hospital, Sun Yat-sen University","place":["Shenzhen, Guangdong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huisheng","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Andrology, The Seventh Affiliated Hospital, Sun Yat-sen University","place":["Shenzhen, Guangdong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zilong","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Burns and Plastic Surgery, The Seventh Affiliated Hospital, Sun Yat-sen University","place":["Shenzhen, Guangdong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1080\/13543784.2025.2573647","article-title":"Androgen receptor pathway signaling inhibitors in development for prostate cancer therapy","volume":"34","author":"Bleve","year":"2025","journal-title":"EXPERT Opin. INV DRUG"},{"key":"B2","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.eururo.2017.08.012","article-title":"Moving towards precision urologic oncology: targeting enzalutamide-resistant prostate cancer and mutated forms of the androgen receptor using the novel inhibitor darolutamide (ODM-201)","volume":"73","author":"Borgmann","year":"2018","journal-title":"Eur. Urol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1134719","DOI":"10.3389\/fendo.2023.1134719","article-title":"Comparative efficacy of second-generation androgen receptor inhibitors for treating prostate cancer: a systematic review and network meta-analysis","volume":"14","author":"Chen","year":"2023","journal-title":"Front. Endocrinol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"7017","DOI":"10.1007\/s00432-023-04658-6","article-title":"Based on ARASENS trial: efficacy and safety of darolutamide as an emerging option of endocrinotherapy for metastatic hormone-sensitive prostate cancer-an updated systematic review and network meta-analysis","volume":"149","author":"Dou","year":"2023","journal-title":"J. CANCER Res. Clin."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1056\/NEJMoa1815671","article-title":"Darolutamide in nonmetastatic, castration-resistant prostate cancer","volume":"380","author":"Fizazi","year":"2019","journal-title":"NEW Engl. J. Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1056\/NEJMoa2001342","article-title":"Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide","volume":"383","author":"Fizazi","year":"2020","journal-title":"NEW Engl. J. Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1097\/JU.0000000000001767","article-title":"Indirect comparison of darolutamide versus apalutamide and enzalutamide for nonmetastatic castration-resistant prostate cancer","volume":"206","author":"Halabi","year":"2021","journal-title":"J. Urol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1200\/JCO.23.02182","article-title":"US food and drug administration approval summary: Talazoparib in combination with enzalutamide for treatment of patients with homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer","volume":"42","author":"Heiss","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.euf.2023.03.024","article-title":"Triplet or doublet therapy in metastatic hormone-sensitive prostate cancer: updated network meta-analysis stratified by disease volume","volume":"9","author":"Hoeh","year":"2023","journal-title":"Eur. Urol. FOCUS"},{"key":"B10","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.euf.2024.11.004","article-title":"Triplet or doublet therapy in metastatic hormone-sensitive prostate cancer patients: an updated network meta-analysis including ARANOTE data","volume":"11","author":"Hoeh","year":"2025","journal-title":"Eur. Urol. FOCUS"},{"key":"B11","doi-asserted-by":"publisher","first-page":"3595","DOI":"10.1200\/JCO.23.00041","article-title":"Darolutamide plus androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer by disease volume and risk subgroups in the phase III ARASENS trial","volume":"41","author":"Hussain","year":"2023","journal-title":"J. Clinical Oncology Official Journal Am. Soc. Clin. Oncol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.eururo.2017.11.038","article-title":"Role of androgen receptor variants in prostate cancer: report from the 2017 mission androgen receptor variants meeting","volume":"73","author":"Luo","year":"2018","journal-title":"Eur. Urol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.euf.2022.08.007","article-title":"Triplet or doublet therapy in metastatic hormone-sensitive prostate cancer patients: a systematic review and network meta-analysis","volume":"9","author":"Mandel","year":"2023","journal-title":"Eur. Urol. FOCUS"},{"key":"B14","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1007\/s10147-024-02485-4","article-title":"Impact of disease volume on survival efficacy of triplet therapy for metastatic hormone-sensitive prostate cancer: a systematic review, meta-analysis, and network meta-analysis","volume":"29","author":"Matsukawa","year":"2024","journal-title":"Int. J. Clin. Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.euo.2022.04.007","article-title":"Treatments for metastatic hormone-sensitive prostate cancer: systematic review, network meta-analysis, and benefit-harm assessment","volume":"5","author":"Menges","year":"2022","journal-title":"Eur. Urol. Oncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"12007","DOI":"10.1038\/srep12007","article-title":"Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies","volume":"5","author":"Moilanen","year":"2015","journal-title":"Sci. REP-UK"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1007\/s10147-020-01777-9","article-title":"Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis","volume":"25","author":"Mori","year":"2020","journal-title":"Int. J. Clin. Oncol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1001\/jama.2025.0228","article-title":"Prostate cancer: a review","volume":"333","author":"Raychaudhuri","year":"2025","journal-title":"JAMA-J Am. Med. Assoc."},{"key":"B19","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1001\/jamaoncol.2022.7762","article-title":"First-line systemic treatment options for metastatic castration-sensitive prostate cancer: a living systematic review and network meta-analysis","volume":"9","author":"Riaz","year":"2023","journal-title":"JAMA Oncol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.2217\/fon-2020-1104","article-title":"Apalutamide, darolutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer: a meta-analysis","volume":"17","author":"Roumiguie","year":"2021","journal-title":"FUTURE Oncol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"4271","DOI":"10.1200\/JCO-24-01798","article-title":"Darolutamide in combination with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer from the phase III ARANOTE trial","volume":"42","author":"Saad","year":"2024","journal-title":"J. Clinical Oncology Official Journal Am. Soc. Clin. Oncol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","article-title":"Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3","volume":"34","author":"Scher","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"4473","DOI":"10.2217\/fon-2022-0943","article-title":"Efficacy and safety of darolutamide in Black\/african-american patients from the phase III ARAMIS study","volume":"18","author":"Shore","year":"2022","journal-title":"Future Oncology Lond. Engl."},{"key":"B24","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1093\/oncolo\/oyad254","article-title":"Efficacy and safety of darolutamide in combination with androgen-deprivation therapy and docetaxel in black patients from the randomized ARASENS trial","volume":"29","author":"Shore","year":"2024","journal-title":"Oncologist"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"NEW Engl. J. Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"469","DOI":"10.6004\/jnccn.2025.0052","article-title":"Prostate cancer, version 3.2026, NCCN clinical practice guidelines in oncology","volume":"23","author":"Spratt","year":"2025","journal-title":"J. Natl. Compr. CANC NE"},{"key":"B27","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/s41391-023-00775-y","article-title":"Safety profile of darolutamide versus placebo: a systematic review and meta-analysis","volume":"27","author":"Turco","year":"2024","journal-title":"PROSTATE CANCER P D."},{"key":"B28","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1007\/s10147-020-01824-5","article-title":"Efficacy and safety of darolutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a sub-group analysis of the phase III ARAMIS trial","volume":"26","author":"Uemura","year":"2021","journal-title":"Int. J. Clin. Oncol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"e2034633","DOI":"10.1001\/jamanetworkopen.2020.34633","article-title":"Clinical efficacy of enzalutamide vs bicalutamide combined with androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: a randomized clinical trial","volume":"4","author":"Vaishampayan","year":"2021","journal-title":"JAMA Netw. OPEN"},{"key":"B30","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1093\/jnci\/djab071","article-title":"Comparison of treatments for nonmetastatic castration-resistant prostate cancer: matching-adjusted indirect comparison and network meta-analysis","volume":"114","author":"Wang","year":"2022","journal-title":"JNCI-J Natl. CANCER I"},{"key":"B31","doi-asserted-by":"publisher","first-page":"402","DOI":"10.4103\/aja20242","article-title":"Network meta-analysis of combination strategies in metastatic hormone-sensitive prostate cancer","volume":"26","author":"Wang","year":"","journal-title":"ASIAN J. Androl."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1038\/s41416-024-02823-3","article-title":"Efficacy and safety evaluation of androgen deprivation therapy-based combinations for metastatic castration-sensitive prostate cancer: a systematic review and network meta-analysis","volume":"131","author":"Wang","year":"","journal-title":"BRIT J. CANCER"},{"key":"B33","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/s41391-021-00395-4","article-title":"Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis","volume":"25","author":"Wenzel","year":"2022","journal-title":"PROSTATE CANCER P D."},{"key":"B34","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s13045-022-01362-9","article-title":"Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-Approved novel therapeutic drugs for solid tumors from 1991 to 2021","volume":"15","author":"Wu","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.eururo.2022.08.002","article-title":"Androgen receptor signaling inhibitors in addition to docetaxel with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis","volume":"82","author":"Yanagisawa","year":"2022","journal-title":"Eur. Urol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"102380","DOI":"10.1016\/j.clgc.2025.102380","article-title":"Do older patients with metastatic hormone-sensitive prostate cancer benefit from triplet or doublet therapy? A network meta-analysis","volume":"23","author":"Zhou","year":"2025","journal-title":"Clin. Genitourin. CANC"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1818807\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T05:42:13Z","timestamp":1779082933000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1818807\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,18]]},"references-count":36,"alternative-id":["10.3389\/fphar.2026.1818807"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1818807","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,18]]},"article-number":"1818807"}}